Antibacterial Agents TRIZ Cases

Lactiplantibacillus plantarum PTA22 degrades oxalic acid and inhibits pathogenic growth, resolving low-fiber diet risks in rabbits.

A modified DNase protein attaches poly(alkylene glycol) moieties through reductive amination to extend in vivo circulation time.

Modified benzimidazole structures maintain high intragastric pH for extended periods, overcoming the temporary efficacy of current ulcer treatments.

Silyl protection and sodium hydride enable high-yield magnolol production without refluxing or complex purification.

Specific synthetic peptides detect antibodies against pathogenic Borrelia burgdorferi, resolving low sensitivity in early Lyme disease stages.

Isolated M. avium protein improves diagnostic sensitivity while reducing vaccine hypersensitivity reactions.

EsaC polypeptide vaccine overcomes antibiotic resistance by converting bacterial presence into protective immunity.

A prophylactic tuberculosis vaccine uses nonionic surfactant homogenization to process Mycobacterium tuberculosis cell wall fragments into an immunotherapeutic agent.

Engineered bacterium uses inducible Type VI secretion system to deliver antibacterial effectors against resistant pathogens.

Segmented thienopyrimidine structures with heteroaryl and morpholino groups resist tumor growth by blocking the PI3 kinase pathway.

Combining Bifidobacterium and Lactobacillus strains restores microbiome-host homeostasis through synergistic bacterial actions.

Oritavancin inhibits C. difficile spore germination, overcoming resistance to conventional antimicrobials.

Phage display selects high-affinity human anti-ALK-1 antibodies that inhibit angiogenesis and tumor growth by blocking the ALK-1/TGF-beta-1/Smad1 pathway.

Single-cycle adenovirus vectors deliver coronavirus immunogens to induce long-term immunity without persistent viral replication.

Polyethylene glycol conjugates extend lysostaphin half-life and reduce immunogenic responses.

A besifloxacin ophthalmic suspension uses a sustained-release carrier to maintain therapeutic drug levels in the eye.

Niclosamide eradicates Helicobacter pylori via respiratory enzyme inhibition, avoiding antibiotic resistance and gut dysbiosis caused by proton pump inhibitors.

PEG linkers resolve aqueous solubility issues while preserving antitumor activity and therapeutic index.

Pyridine derivatives block Kv1.5 channels to treat arrhythmias without delaying ventricular repolarization or causing proarrhythmia.

Edible films incorporating small molecule antimicrobials deliver controlled release to inhibit resistant bacteria, addressing foodborne pathogen risks.

Lipophilic bases and solvents stabilize mupirocin while bioadhesives increase skin retention.

Anti-CXCL13 antibodies resolve IgA deficiency by blocking CXCL13 activity to restore mucosal immunity and reduce bacterial loads.

Targeted mutagenesis of bacteriophage tail fiber binding loops creates combinatorial libraries that evade bacterial resistance mechanisms.

Universal surface proteins M2, SP2, SP4, and SP7 provide broad serotype coverage while reducing manufacturing complexity.

Formula I compounds treat multidrug-resistant infections by combining with efflux pump inhibitors to restore antibiotic efficacy against resistant pathogens.

Combining hop extract with phenylpropanol yields synergistic biocidal activity, reducing required concentrations to lower skin irritation risks.

Killed Haemophilus influenzae vaccine reduces airway colonization, decreasing exacerbations and hospitalizations.

Novel fused-imidazolyl compounds combat antibiotic-resistant pathogens by bypassing existing bacterial resistance mechanisms.

Heterocyclic compounds combine antibacterial activity with beta-lactamase inhibition to overcome bacterial resistance mechanisms.

Segmented adjuvant system prevents immunogen interactions while enabling safe intradermal administration.

Cyclic peptides from Staphylococcus lugdunensis destroy resistant bacteria like MRSA and VRSA, overcoming antibiotic failure.

Structural modifications extend carbapenem half-life, reducing dosing frequency and bacterial resistance.

Formula I compounds inhibit protein tyrosine kinase activity through specific structural features.

Thermal treatment of Streptococcus uberis biofilms yields a purified immunogenic agent for bovine mastitis vaccines.

Hibiscus polyphenols maintain acidic pH to treat cystitis without antibiotic resistance risks.

Segmented VHH domains target multiple viral receptors simultaneously, resolving specificity and efficacy trade-offs in antiviral therapy.

Dual action compounds target multiple bacterial sites to suppress antibiotic resistance, treating infections caused by multidrug-resistant pathogens like MRSA.

Antagonistic polypeptides bind human TNFR2 to block regulatory T cell suppression, restoring tumor-reactive T lymphocyte activity.

Antibody-conjugated modulators target complement activation sites to resolve the contradiction between systemic efficacy and safety.

Segmented molecular structures inhibit CCR2 receptors, reducing macrophage-induced inflammation in asthma and COPD.

QRFSR peptide from BPLP protein inhibits NEP and APN, resolving limited inhibitor specificity.

2-aminoimidazole-phenyl compounds prevent bacterial adhesion and biofilm development on medical substrates.

Amino acid substitutions in IgG2 and IgG3 constant regions prevent aggregate formation at low pH, enabling stable drug production.